Editor's note

Originally published November 2020. mRNA influenza vaccines have advanced significantly since this article was written. For current modelling of the influenza and combination respiratory vaccine market, see VAMV036 - Flu COMBO Vaccines Forecast (2026, New!).

The Market at a Glance

Seasonal influenza causes an estimated 3-5 million severe illness cases and between 290,000 and 650,000 respiratory deaths annually worldwide (WHO). Despite being one of the oldest vaccine categories, the influenza market continued to grow through the late 2010s as national programmes widened recommendations beyond traditional high-risk groups. By 2020, the US recommended universal vaccination for all individuals aged 6 months and above, and European programmes were expanding into mid-adult cohorts.

The global influenza vaccine market was valued at approximately $5.5-6 billion in 2019. The US accounted for approximately 50% of global revenues. Product mix was shifting: in the US, quadrivalent inactivated vaccine (QIV) represented approximately 99% of distributed doses, with egg-based manufacturing still dominant despite investment in cell-based and recombinant alternatives.

Annual deaths from influenza · WHO estimate
290-650k

Estimated annual respiratory deaths attributable to seasonal influenza globally (WHO). Vaccination remains the most effective preventive tool despite suboptimal and variable efficacy.

The Evolving Product Mix

As of November 2020, Seqirus had established cell-based Flucelvax as the leading non-egg US alternative, while Sanofi's Supemtek (recombinant, quadrivalent) had received EMA approval for European launch. Sanofi's high-dose Fluzone HD and adjuvanted Fluad remained the leading US products for adults aged 65 and above - a premium segment with significant margin advantages over standard-dose formulations. Efluelda (MF59-adjuvanted QIV) was Sanofi's emerging European premium positioning for older adults.

The mRNA Horizon

In November 2020, no mRNA influenza vaccine had entered advanced clinical testing. But the near-simultaneous Phase 3 approaches of BNT162b2 and mRNA-1273 had demonstrated that the mRNA platform was industrially viable at scale. Both Sanofi and Moderna had announced mRNA influenza programmes, and the strategic implications for the established influenza market were beginning to be taken seriously.

The key questions: Would mRNA influenza vaccines offer a meaningful efficacy advantage over established QIV? Could cold chain requirements be managed cost-effectively in mass vaccination? And how would payers respond to premium pricing in a market where existing vaccines were already cheaply procured? These questions remain central today - see our updated analysis in VAMV036 - Flu COMBO Vaccines Forecast.